December 2017December 2017
New Product - Sativex
Sativex (nabiximols) contains cannabinoid botanical drug substances (partially purified extracts) produced from cultivated Cannabis sativa L. plants specifically bred to produce their cannabinoid content as high delta-9-tetrahydrocannabinol (THC) or high cannabidiol (CBD) chemotypes. Cannabinoid receptor CB1 is found mainly in nerve terminals in the CNS where it modulates neurotransmitter release, and CB2 is found primarily in cells of the immune system. THC acts as a partial agonist at both CB1 and CB2. Sativex is indicated as treatment, for symptom improvement in moderate to severe spasticity due to multiple sclerosis (MS) which has not responded adequately to other anti-spasticity medication and demonstrates clinically significant improvement in spasticity related symptoms during an initial trial of therapy. Sativex is contraindicated with: any known or suspected history or family history of schizophrenia, or other psychotic illness; history of severe personality disorder or other significant psychiatric disorder other than depression associated with the underlying condition; breastfeeding. Sativex oromucosal spray solution (nabiximols 80 mg/mL ≡ THC 27 mg/mL, CBD 25 mg/mL; 100 microlitres/spray) is available in a pack containing 3 x 10 mL (90 actuation) metered dose sprays.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au